000054704 001__ 54704
000054704 005__ 20200423204411.0
000054704 0247_ $$2pmid$$apmid:16497506
000054704 0247_ $$2DOI$$a10.1016/j.apradiso.2005.12.020
000054704 0247_ $$2WOS$$aWOS:000237196400013
000054704 0247_ $$2Handle$$a2128/413
000054704 037__ $$aPreJuSER-54704
000054704 041__ $$aeng
000054704 082__ $$a530
000054704 084__ $$2WoS$$aChemistry, Inorganic & Nuclear
000054704 084__ $$2WoS$$aNuclear Science & Technology
000054704 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000054704 1001_ $$0P:(DE-HGF)0$$aAl-Abyad, M.$$b0
000054704 245__ $$aNuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via the (n,p) reaction: Evaluation of excitation function and its validation via integral cross-section measurement using a 14 MeV d(Be) neutron source
000054704 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2006
000054704 300__ $$a717 - 724
000054704 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000054704 3367_ $$2DataCite$$aOutput Types/Journal article
000054704 3367_ $$00$$2EndNote$$aJournal Article
000054704 3367_ $$2BibTeX$$aARTICLE
000054704 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000054704 3367_ $$2DRIVER$$aarticle
000054704 440_0 $$0563$$aApplied Radiation and Isotopes$$v64$$x0969-8043
000054704 500__ $$aRecord converted from VDB: 12.11.2012
000054704 520__ $$aNuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via (n,p) reactions on the target nuclei 32S, 64Zn, 67Zn, 89Y, (90)Zr and 153Eu, respectively, are discussed. The available information on each excitation function was analysed. From the recommended data set for each reaction the average integrated cross section for a standard 14 MeV d(Be) neutron field was deduced. The spectrum-averaged cross section was also measured experimentally. A comparison of the integrated value with the integral measurement served to validate the excitation function within about 15%. A fast neutron source appears to be much more effective than a fission reactor for production of the above-mentioned radionuclides in a no-carrier-added form via the (n,p) process. In particular, the possibility of production of high specific activity 153Sm is discussed.
000054704 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000054704 588__ $$aDataset connected to Web of Science, Pubmed
000054704 650_2 $$2MeSH$$aNeutrons
000054704 650_2 $$2MeSH$$aRadioisotopes: chemistry
000054704 650_2 $$2MeSH$$aRadiopharmaceuticals: chemistry
000054704 650_7 $$00$$2NLM Chemicals$$aRadioisotopes
000054704 650_7 $$00$$2NLM Chemicals$$aRadiopharmaceuticals
000054704 650_7 $$2WoSType$$aJ
000054704 65320 $$2Author$$atherapeutic radionuclide
000054704 65320 $$2Author$$a(n,p) reaction
000054704 65320 $$2Author$$aexcitation function
000054704 65320 $$2Author$$aintegral test
000054704 65320 $$2Author$$a14MeV d(Be) neutron source
000054704 65320 $$2Author$$anuclear model calculation
000054704 7001_ $$0P:(DE-Juel1)VDB43831$$aSpahn, I.$$b1$$uFZJ
000054704 7001_ $$0P:(DE-Juel1)VDB21537$$aSudár, S.$$b2$$uFZJ
000054704 7001_ $$0P:(DE-HGF)0$$aMorsy, M.$$b3
000054704 7001_ $$0P:(DE-HGF)0$$aComsan, M. N. H.$$b4
000054704 7001_ $$0P:(DE-HGF)0$$aCsikai, J.$$b5
000054704 7001_ $$0P:(DE-Juel1)VDB1300$$aQaim, S. M.$$b6$$uFZJ
000054704 7001_ $$0P:(DE-Juel1)131816$$aCoenen, H. H.$$b7$$uFZJ
000054704 773__ $$0PERI:(DE-600)1499873-7$$a10.1016/j.apradiso.2005.12.020$$gVol. 64, p. 717 - 724$$p717 - 724$$q64<717 - 724$$tApplied radiation and isotopes$$v64$$x0969-8043$$y2006
000054704 8567_ $$uhttp://hdl.handle.net/2128/413$$uhttp://dx.doi.org/10.1016/j.apradiso.2005.12.020
000054704 8564_ $$uhttps://juser.fz-juelich.de/record/54704/files/Elsevier_INC_AlAbyadNucl.pdf$$yOpenAccess
000054704 8564_ $$uhttps://juser.fz-juelich.de/record/54704/files/Elsevier_INC_AlAbyadNucl.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000054704 8564_ $$uhttps://juser.fz-juelich.de/record/54704/files/Elsevier_INC_AlAbyadNucl.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000054704 8564_ $$uhttps://juser.fz-juelich.de/record/54704/files/Elsevier_INC_AlAbyadNucl.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000054704 909CO $$ooai:juser.fz-juelich.de:54704$$pdnbdelivery$$pVDB$$pdriver$$popen_access$$popenaire
000054704 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000054704 9141_ $$y2006
000054704 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000054704 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000054704 9201_ $$0I:(DE-Juel1)VDB53$$d31.12.2006$$gINC$$kINC$$lInstitut für Nuklearchemie$$x0
000054704 970__ $$aVDB:(DE-Juel1)85555
000054704 980__ $$aVDB
000054704 980__ $$aJUWEL
000054704 980__ $$aConvertedRecord
000054704 980__ $$ajournal
000054704 980__ $$aI:(DE-Juel1)INM-5-20090406
000054704 980__ $$aUNRESTRICTED
000054704 980__ $$aFullTexts
000054704 9801_ $$aFullTexts
000054704 981__ $$aI:(DE-Juel1)INM-5-20090406